Skip to main
GKOS

Glaukos (GKOS) Stock Forecast & Price Target

Glaukos (GKOS) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 58%
Buy 33%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Glaukos is well-positioned to continue its strong growth trajectory, with innovative products such as the iDose TR and potentially game-changing LCD approvals. A survey of ophthalmologists reveals a high adoption rate for iDose TR, as it addresses the need for long-term, dropless treatment of glaucoma, and could contribute significantly to the company's revenue. The company has a strong pipeline of products and a solid financial position, making it an attractive investment opportunity in the ophthalmic pharmaceutical and medical technology industry.

Bears say

Glaukos is facing many challenges in the near future, including a proposed LCD process that could significantly impact their sales of the iDose TR implant. Our analysis reveals that many physicians believe the LCDs will lead to a decrease in iDose volumes, and they are uncertain about how this will affect their patients' care. Furthermore, the LCDs do not reflect the current state of clinical evidence supporting the use of iDose and may limit treatment options for patients. These hurdles, combined with a limited FDA label and market access barriers, lead to a negative outlook on Glaukos's stock.

Glaukos (GKOS) has been analyzed by 12 analysts, with a consensus rating of Buy. 58% of analysts recommend a Strong Buy, 33% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Glaukos (GKOS) Forecast

Analysts have given Glaukos (GKOS) a Buy based on their latest research and market trends.

According to 12 analysts, Glaukos (GKOS) has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $177, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $177, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Glaukos (GKOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.